SCHEMBL3528653

SCHEMBL3528653

Cc1c(Br)c(=O)n(-c2ccc(F)cc2)n1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
FPR2 P25090 1/20 0.46
ALDH1A1 P00352 3/20 0.44
ALOX15 P16050 2/20 0.44
BCHE P06276 1/20 0.44
PTGS2 P35354 1/20 0.44
GAA P10253 2/20 0.43
LMNA P02545 2/20 0.42
ADORA3 P0DMS8 1/20 0.42
HTR7 P34969 1/20 0.42
TSHR P16473 2/20 0.41
CYP1A2 P05177 1/20 0.41
THRB P10828 1/20 0.41
NAPRT Q6XQN6 1/20 0.41
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
G6PD P11413 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23907007 0.86 ALDH1A1 (0.46) KMT2AMEN1FPR2ALDH1A1ALOX15
SCHEMBL23907025 0.83 GAA (0.48) KMT2AMEN1FPR2ALDH1A1ALOX15
SCHEMBL23907012 0.82 BCHE (0.64) KMT2AMEN1ALDH1A1ALOX15BCHE
SCHEMBL14949021 0.82 KMT2A (0.54) KMT2AMEN1FPR2ALDH1A1ALOX15
SCHEMBL23907011 0.82 FPR2 (0.49) KMT2AMEN1FPR2ALDH1A1ALOX15
SCHEMBL23907006 0.80 BCHE (0.53) KMT2AMEN1ALDH1A1ALOX15BCHE
SCHEMBL23907014 0.80 KMT2A (0.52) KMT2AMEN1FPR2ALDH1A1ALOX15
SCHEMBL4318702 0.79 KMT2A (0.51) KMT2AMEN1FPR2ALDH1A1ALOX15
SCHEMBL6260574 0.79 BCHE (0.70) KMT2AMEN1FPR2ALDH1A1ALOX15
SCHEMBL3529330 0.79 ALDH1A1 (0.38) KMT2AMEN1FPR2ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652057-B2 Pyrazolones as 11b-HSD1 inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2010-01-26 US disclosed
EP-1924562-A2 PYRAZOLONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-05-28 EP disclosed
WO-2007025880-A2 PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-03-08 WO disclosed
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes HSD11B1, HSD17B1, HSD17B7 KMT2A 4086/4885MEN1 1683/4885FPR2 3827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.